Summit Therapeutics SMMT Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's total liabilities?
- Summit Therapeutics (SMMT) reported total liabilities of $101.92M in Q1 2026.
- How has Summit Therapeutics's total liabilities changed year-over-year?
- Summit Therapeutics's total liabilities increased by 158.1% year-over-year, from $39.49M to $101.92M.
- What is the long-term trend for Summit Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Summit Therapeutics's total liabilities has grown at a 32.0% compound annual growth rate (CAGR), from $23.05M to $92.32M.
- What does total liabilities mean?
- The total amount of all money the company owes to others.
- How do you interpret total liabilities?
- A high total liability relative to equity indicates higher financial leverage and potential risk, especially for pre-revenue biotech firms.
- How does total liabilities compare across companies?
- Used to calculate debt-to-equity ratios and assess overall financial health relative to industry peers.